Dermatology

In instances when longer term or repeat treatment is required, continued use of IG should be based on objective measures of effectiveness established at the outset of treatment. These measures should be assessed no later than 6 months after initiation of long-term treatment and at least annually thereafter. If clinical effectiveness has not been achieved or sustained, IG should be discontinued.

Autoimmune blistering diseases

Recommended Indications in which IG can be used

Order Number: D1-ABD

Pyoderma gangrenosum

Recommended Indications in which IG can be used

Order Number: D2-PG

Scleromyxedema

Recommended Indications in which IG can be used

Order Number: D3-S

Toxic epidermal necrolysis (TEN)/Stevens–Johnson syndrome (SJS)

Not for Routine Use

Order Number: D4-TEN/SJS